These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22582908)

  • 1. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.
    Ezra N; Jorizzo J
    Clin Exp Dermatol; 2012 Jun; 37(4):327-34. PubMed ID: 22582908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
    Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T
    Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal use of antimalarials in treating cutaneous lupus erythematosus.
    Wozniacka A; McCauliffe DP
    Am J Clin Dermatol; 2005; 6(1):1-11. PubMed ID: 15675885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
    Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
    Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.
    Chasset F; Francès C; Barete S; Amoura Z; Arnaud L
    J Am Acad Dermatol; 2015 Apr; 72(4):634-9. PubMed ID: 25648824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous lupus erythematosus: update of therapeutic options part I.
    Kuhn A; Ruland V; Bonsmann G
    J Am Acad Dermatol; 2011 Dec; 65(6):e179-93. PubMed ID: 20739095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.
    Chasset F; Bouaziz JD; Costedoat-Chalumeau N; Francès C; Arnaud L
    Br J Dermatol; 2017 Jul; 177(1):188-196. PubMed ID: 28112801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study].
    Lardet D; Martin S; Truchetet F; Cuny JF; Virion JM; Schmutz JL
    Rev Med Interne; 2004 Nov; 25(11):786-91. PubMed ID: 15501347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment.
    Jewell ML; McCauliffe DP
    J Am Acad Dermatol; 2000 Jun; 42(6):983-7. PubMed ID: 10827400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptor-9 signaling and decreased efficacy of antimalarial drugs in smokers with cutaneous lupus erythematosus.
    Kwatra SG
    J Am Acad Dermatol; 2015 Aug; 73(2):e79. PubMed ID: 26184008
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to hydroxychloroquine due to smoking in a patient with lupus erythematosus tumidus.
    Hügel R; Schwarz T; Gläser R
    Br J Dermatol; 2007 Nov; 157(5):1081-3. PubMed ID: 17854374
    [No Abstract]   [Full Text] [Related]  

  • 13. Update on the management of cutaneous lupus erythematosus.
    Callen JP
    Br J Dermatol; 2004 Oct; 151(4):731-6. PubMed ID: 15491411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of antimalarial-refractory cutaneous lupus erythematosus.
    Callen JP
    Lupus; 1997; 6(2):203-8. PubMed ID: 9061669
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know.
    Teboul A; Arnaud L; Chasset F
    J Dermatol; 2024 Jul; 51(7):895-903. PubMed ID: 38482997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus".
    Callen JP
    Arch Dermatol; 2011 Nov; 147(11):1267-8. PubMed ID: 22106112
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database.
    Kuhn A; Sigges J; Biazar C; Ruland V; Patsinakidis N; Landmann A; Amler S; Bonsmann G;
    Br J Dermatol; 2014 Sep; 171(3):571-9. PubMed ID: 24673427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of smoking in cutaneous lupus erythematosus.
    Piette EW; Foering KP; Chang AY; Okawa J; Ten Have TR; Feng R; Werth VP
    Arch Dermatol; 2012 Mar; 148(3):317-22. PubMed ID: 22105815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The different faces of cutaneous lupus erythematosus.
    Renner R; Sticherling M
    G Ital Dermatol Venereol; 2009 Apr; 144(2):135-47. PubMed ID: 19357621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoking enhances Toll-like receptor-9 responsiveness and type I interferon production in plasmacytoid dendritic cells in patients with cutaneous lupus erythematosus.
    Chasset F; Francès C; Arnaud L
    J Am Acad Dermatol; 2015 Aug; 73(2):e81. PubMed ID: 26184009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.